Recent Updates
Recently added Catalysts

Cenderitide

Phase 2

Heart Failure | Small molecule | Cardiovascular |Capricor Therapeutics, Inc.|Last Updated: Feb 10, 2020

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials2
Total Enrollment22
FDA Designations
No designations recorded
Clinical trial landscape

Cenderitide · 2 trials · 2 indications

Phase 2 1Phase 1/2 1
NCT02359227Safety Study of Cenderitide in Stable Chronic Heart FailureHeart Failure
COMPLETED14 Analytics
PHASE2COMPLETED
Safety Study of Cenderitide in Stable Chronic Heart Failure
Heart Failure
NCT0235922714
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
CenderitideDRUGCenderitide is a dual receptor natriuretic peptide.
PlaceboDRUGPlacebo control
Unlock Study Design Details
Competitive Landscape -Heart Failure 113 trials

Top 20 of 31 competitors

CompanyTickerTrialsLead PhaseDrugs
Novo Nordisk A/S Sponsored ADR Class BNVO8PHASE3Ziltivekimab
AstraZeneca PLCAZN6PHASE3Undisclosed
Cytokinetics, IncorporatedCYTK2PHASE3Omecamtiv Mecarbil
Amgen Inc.AMGN1PHASE3Maridebart cafraglutide
DexCom, Inc.DXCM1PHASE3Sotagliflozin
Pfizer Inc.PFE1PHASE2Low Dose PF-07328948
Merck & Co., Inc.MRK1PHASE2Vericiguat
Bristol-Myers Squibb CompanyBMY1PHASE2BMS-986435
Novartis AG Sponsored ADRNVS2PHASE1HJB647 low dose
Tectonic Therapeutic IncTECX1PHASE2TX000045- Dose A, TX000045- Dose B
BioCardia, Inc.BCDA2PHASE1CardiALLO Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells
ICON PlcICLR1PHASE2JTT-861
Edwards Lifesciences CorporationEW10N/AUndisclosed
Boston Scientific CorporationBSX4N/AUndisclosed
Medtronic PlcMDT5 - Undisclosed
Abbott LaboratoriesABT8N/AUndisclosed
Colorado Prevention CenterBAYRY1PHASE3Finerenone
Illumina, Inc.ILMN1PHASE218F-metaFluorobenzylguanidine, Rubidium-82
Moderna, Inc.MRNA1 - Undisclosed
CVRx, Inc.CVRX2 - Undisclosed
Unlock Competitive Intelligence